Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia. However, what makes an antipsychotic 'atypical' remains unclear. We recently found that the T102C polymorphism in the 5-HT 2A receptor gene could affect risperidone's efficacy for negative symptoms. The present study investigated the effect of the Ser311Cys polymorphism in the dopamine D 2 receptor (DRD2) gene on risperidone treatment response. A total of 123 Han Chinese patients with acutely exacerbated schizophrenia were given risperidone for up to 42 days. Clinical manifestations were measured bi-weekly with Positive and Negative Syndrome Scale (PANSS) and Nurses' Observation Scale for Inpatients Evaluation (NOSIE, for assessment of social function). For adjusting the within-subject dependence over repeated assessments, multiple linear regression with generalized estimating equation methods was utilized to analyse the effects of Ser311Cys polymorphism and other covariates on clinical performance. Compared with patients who had the Ser311Ser genotype, patients with the Ser311Cys genotype had lower scores on PANSS Positive, Negative, General Psychopathology and Cognitive subscales and NOSIE, after adjustment for 5-HT 2A T102C polymorphisms and other confounders. The 5-HT 2A T102C polymorphism had marginal influences on PANSS Total and Negative subscale scores. Male gender, fewer previous hospitalizations, and higher risperidone dose predicted better treatment response after control for other variables. The preliminary results suggest that variations in the DRD2 gene influence risperidone treatment response for positive, negative, and cognitive symptoms, general psychopathology, and social functioning. Several clinical factors may also contribute to inter-individual differences in risperidone treatment response.
Introduction
Schizophrenia is a chronic mental disorder and its symptoms are primarily subdivided into two subtypes, positive and negative (Andreasen, 1985 ; Chang et al., 1990) . The positive symptoms include delusions and hallucinations ; the negative symptoms, blunted affect and social withdrawal. Later factor analysis studies also revealed another syndrome factor (disorganization) (Marengo et al., 2000 ; Toomey et al., 1998) . The treatment of schizophrenic patients with a typical antipsychotic or an atypical antipsychotic has been successful against positive symptoms. A main question is whether atypical agents are superior in the treatment of negative symptoms than typical agents (Leucht et al., 1999 (Leucht et al., , 2003 .
Although atypical antipsychotics are becoming the mainstay for schizophrenia treatment, what makes an antipsychotic ' atypical' remains unclear (Emilien et al. , the reason for this lack of clarity is the limited number of appropriate animal models that can model schizophrenia symptoms and that can be used for drug screening (Corbett et al., 1993 ; Ellenbroek et al., 1989 ; Pouzet et al., 2002) . Thus, it is of great importance to determine how antipsychotics improve symptom domains in patients with schizophrenia. A balance of 5-HT 2A -receptor occupancy and dopamine D 2 -receptor occupancy probably underlies the beneficial therapeutic action of risperidone, especially on negative symptoms (Leysen et al., 1994) . In agreement, our recent study (Lane et al., 2002a) demonstrated that variations in the 5-HT 2A receptor gene could influence risperidone treatment response (particularly for negative symptoms rather than positive symptoms). Of note, it has been proposed that the atypical antipsychotic effect can be produced by appropriate modulation of the dopamine D 2 receptor (DRD2) alone ; the blockade of other receptors is neither necessary nor sufficient (Kapur et al., 2000) . Several polymorphisms have been described in the DRD2 gene (Arranz et al., 1998a ; Itokawa et al., 1993 ; Schafer et al., 2001) . Of them, x141C Ins/Del (in the promoter region) (Arranz et al., 1998a ; Malhotra and Goldman, 1999 ; Yamanouchi et al., 2003) and TaqI (a silent variant) (Yamanouchi et al., 2003) have been examined for their association with efficacy of atypical antipsychotics. Arranz et al. (1998a) studied the x141C Ins/Del polymorphism in a sample of 151 clozapine-(the prototype of atypical antipsychotics) treated patients of British origin and in another sample of 146 Han Chinese schizophrenic patients treated with a variety of antipsychotics. No association was found between this polymorphism and clinical response in either of the two samples. Malhotra and Goldman (1999) detected an association between this polymorphism and clozapine response ; however, the number and characteristics of the subjects were undisclosed. Yamanouchi et al. (2003) examined six candidate polymorphisms (including DRD2 x141delC and TaqI) in 73 Japanese patients who were given risperidone treatment. A DRD2 haplotype tended to correlate with better clinical performance. Compared with patients who had Ins-A2/Ins-A2 diplotype (n= 25), patients with Ins-A2/Del-A1 diplotype (n=10) showed greater improvement.
Moreover, there is a missense variant of the DRD2 gene resulting in a substitution of serine with cysteine at codon 311 (Ser311Cys) (Itokawa et al., 1993) . Ser311 lies in the middle portion of the third intracellular loop of the short form of the DRD2, which can modulate or take part in the receptor-G-protein interaction. It has been shown that risperidone, unlike several other antipsychotics, has no differences in binding affinities and potencies for this DRD2 variant (Cravchik et al., 1999) . The Cys311 variant, however, was markedly less effective in inhibiting cAMP synthesis than the more prevalent form (Ser311) (Cravchik et al., 1996) . Replacement of Ser311 with Cys311 might also affect the regulation of desensitization and internalization of the receptor (Itokawa et al., 1996) , or it might produce a conformational change of the receptor protein by forming a new disulphide bond (Arinami et al., 1994) . Functional differences between DRD2 variants may, thus, be related to genetically determined differences in response to antipsychotic treatment.
Antecedent studies showed that, when treated with typical antipsychotics, patients carrying Cys311 had shorter duration of past and current admission (Arinami et al., 1994) or were less likely to be treatmentresistant to typical agents (Shaikh et al., 1994) than those without Cys311. In the Shaikh et al. (1994) study only two treatment-resistant patients carried the Cys311 allele and both individuals responded to subsequent clozapine treatment. Therefore, whether this polymorphism influences antipsychotics (particularly atypicals) efficacy for positive or negative symptoms deserves further investigation.
Most of the previous genetic-response studies on neurotransmitter receptors or transporters cannot be reconfirmed (Arranz et al., 2000 ; Malhotra and Goldman, 1999 ; Masellis et al., 2000 ; Staddon et al., 2002) . These pharmacogenetic studies did not usually take into account other determinants such as gender, age, education level, diagnosis subtype, age at illness onset, duration of illness, and hospitalization history (Lane et al., 2002b ; Lieberman et al., 1994) . The current study aimed to explore the influence of the DRD2 Ser311Cys polymorphism on risperidone response for positive and negative symptoms and social function after adjustment for the effects of treatment duration, baseline psychopathology, drug dose, and other patient-related variables. Since the 5-HT 2A T102C polymorphism could also influence risperidone response for negative symptoms (Lane et al., 2002a) , this genetic factor was also taken into account.
Method

Subjects
This prospective, open-labelled, and repeatedmeasures study was conducted in the in-patient unit of China Medical University Hospital. The protocol was approved by the Institution's Review Board and carried out in accordance with Declaration of Helsinki. All newly hospitalized schizophrenic patients with acute exacerbation were screened and evaluated by experienced psychiatrists. The Structured Clinical Interview for DSM-IV (APA, 1994) was conducted for the diagnosis. Han Chinese patients in Taiwan entered into this study if they (1) were physically healthy and had all laboratory parameters within normal limits, (2) were aged 18-60 yr, (3) satisfied DSM-IV criteria for schizophrenia, (4) had a minimum baseline total score of 60 on the Positive and Negative Syndrome Scale (PANSS ; Kay et al., 1987) , (5) had neither current nor past DSM-IV diagnosis of mood disorders or substance (including alcohol) abuse, (6) were non-smokers, (7) had not received depot antipsychotics during the preceding 6 months, (8) had no history suggesting that antipsychotic treatment would be contraindicated, and (9) had never received atypical antipsychotics before. After complete description of the study to the subjects, written informed consent was obtained in line with the Institution's Review Board guidelines.
Study design and intervention
During the washout period, the subjects were placed on a placebo for 7 d, which could be shortened to a minimum of 1 d for patients with extremely emergent psychotic symptoms. Then, during the risperidone monotherapy period, the drug dose was gradually titrated to the target dose 6 mg/d (or lower, in case of intolerance) within 1 wk. From day 8 to day 42, the dosage remained the same as that used on day 7, or could be reduced on day 14 or day 28 after the drugsafety evaluation (see ' Assessments' below). Nursing staff closely monitored and ensured the patients' compliance. The dosing strategy was based upon our recent work (Lane et al., 2000) : nearly 60 % of 30 acute schizophrenia in-patients tolerated a target dose of 6 mg/d ; for the other 40 % of patients, reducing doses to a mean of 3.6 mg/d for the relief of side-effects still yielded efficacy.
Assessments
Drug efficacy and safety assessments were conducted on days 0, 14, 28 and 42. An experienced research psychiatrist (H.-Y.L.), unaware of the genotypes of the patients, administered all efficacy and safety rating instruments. Patients' symptoms were assessed by the PANSS and its Positive, Negative, and General Psychopathology subscales (Kay et al., 1987) . In addition, the PANSS has a ' Cognitive ' subscale, which also somewhat represents 'disorganization of thought and behaviour ' and consists of five items : conceptual disorganization, difficulty in abstract thinking, mannerism and posturing, disorientation, and lack of judgement and insight (Lindenmayer et al., 1994) . Social functioning and activities of daily living were determined by the Nurses' Observation Scale for Inpatients Evaluation (NOSIE ; Honigfeld and Klett, 1965) . The NOSIE thus complements the PANSS (that focuses more on psychopathology). Drug safety was evaluated by routine physical and neurological examinations, laboratory tests, the Extrapyramidal Symptom Rating Scale (ESRS ; Chouinard et al., 1980) , and the Udvalg for Kliniske Underso-gelser (UKU) Side Effect Rating Scale (Lingjaerde et al., 1987) . The ESRS was designed to evaluate three types of extrapyramidal symptoms : parkinsonism, dystonia, and dyskinesia (Chouinard et al., 1980) . Other side-effect profiles were determined by the UKU Scale.
Genotyping
Patients were genotyped for DRD2 and 5-HT 2A polymorphisms by polymerase chain reaction amplification of DNA and then digestion with Sau96I for detection of Ser311Cys (Arinami et al., 1994) and with MspI for detection of T102C (Chen et al., 1997) . DNA fragments were visualized by 2 % agarose gel electrophoresis and staining with ethidium bromide.
Statistical analysis
For between-group comparisons, two-tailed x 2 tests or Fisher's exact tests were used for categorical data, while two-tailed Mann-Whitney U tests were used for dimensional data. For within-group comparisons, two-tailed Wilcoxon Signed Ranks tests were used for dimensional data. These non-parametric statistical methods were used because the distributions of the dependent measures were not normally distributed.
The main purpose of this study, however, was to examine the association between the DRD2 Ser311Cys polymorphism and risperidone effectiveness after controlling for other variables. PANSS Total and subscales scores and NOSIE total score were used as measures of response to risperidone. Potential prognostic factors included DRD2 and 5-HT 2A polymorphisms as well as treatment duration (weeks 0-6), baseline PANSS subscale or NOSIE score, end-point risperidone dose, gender, age, education level, diagnosis subtype, age at illness onset, duration of illness, and number of previous hospitalizations. To evaluate the possible effects of the prognostic factors on the response values, the multiple linear regression model, which is capable of controlling for other prognostic factors, was utilized.
Because multiple linear regression can be applied only if the distribution of the response values is symmetrical (Bolton, 1984) , we examined the distribution patterns of the PANSS or NOSIE scores, using the ' Kolmogorov D' package in SAS/INSIGHT, version 8.2 (SAS Institute Inc., 1999). We found that the distributions of these scores in our subjects were skewed to right. Since logarithmic transformation can convert the skew-to-right distribution to a normal distribution (Bolton, 1984 ; Lane et al., 1999a) , the value of each PANSS Total or subscale score or the NOSIE total score was transformed to its natural logarithm to obtain a normal distribution prior to multiple regression analyses. For example, the value of testing statistics for distribution of PANSS Total scores was 0.068 (p<0.01) and for distribution of natural logarithms of PANSS Total scores was 0.0368 (p=0.128). The result with a p value >0.05 means the data are more likely to be normally distributed. Therefore, the PANSS Total scores were not likely to be normally distributed but the natural logarithms of the PANSS Total scores were more likely to be.
Another basic requirement for conventional multiple linear regression is that the collected data should be independent. In other words, each subject should provide one and only one record in the dataset. For repeated-measures studies (such as the current one), the longitudinal follow-up data obtained from the same subject, however, are intra-individually related and violate the 'independent ' requirement. To adjust this within-subject dependence effect, Zeger et al. (1988) set up a statistical method named the generalized estimating equation for multiple linear regression in repeated-measures studies. In the current study, we thus conducted the generalized estimating equation analysis, using SAS/STAT, version 8.2 (SAS Institute Inc., 1999), to control for time effects, baseline psychopathology, and other patient-related variables. Statistical significance was defined as p<0.05. Bonferroni correction seemed inappropriate in the current case because several of the dependent measures were inter-correlated.
Results
Patient disposition and characteristics
In total, 123 patients at least completed the assessments on days 0 and 14 (the first post-treatment visit) and were eligible for data analysis. The number of patients actively participating on days 28 and 42 were 117 and 102 respectively. The reasons for premature discontinuation were concurrent somatic illness (n= 2), sufficient response (n=11), poor response (n=4), and non-compliance (n=4). The mean age of the 123 patients was 34.0¡9.7 yr (68 male, 55 female). The mean¡S.D. age at illness onset was 24.5¡7.9 yr, the mean illness duration was 105.6¡85.0 months, the mean number of previous hospitalizations was 1.9¡ 2.5, and the mean level of education was 10.7¡2.9 yr. The distribution of subtypes was 86 paranoid, 14 disorganized, and 23 undifferentiated. Thirty-one patients did not tolerate the target dose of 6 mg/d and the mean risperidone dose in all 123 subjects at endpoint was 4.0¡1.4 mg/d. Since our dosing strategy was to reduce side-effects if possible, adverse events in the subjects were minimal (if any), short-lived, and resolved spontaneously or after dose reduction, without requiring medical treatment. No clinically significant and relevant abnormal laboratory test results were recorded. No patients withdrew from the trial due to adverse reactions.
As shown in Table 1 , the two DRD2 genotype groups were similar in demographics. The genotype distribution was Ser/Ser in 111 patients and Ser/Cys in 12 patients. No Cys/Cys patients were found. The allele frequency of Cys311 was similar to that in other studies enrolling Japanese (Arinami et al., 1994 ; Hori (Gejman et al., 1994 ; Shaikh et al., 1994 ; Spurlock et al., 1998) . The 5-HT 2A genotype distribution was T/T in 54 patients, C/C in 12, and T/C in 57. The allele frequency of T102 was similar to that in the earlier study with Han Chinese (Corbett et al., 1993 ) but higher than that in Western individuals (Arranz et al., 1998b ; Williams et al., 1996) .
Determinants for clinical performance
The mean¡S.D. PANSS Total scores declined during risperidone treatment : 89.4¡16.2 at baseline and 70.0¡16.0 at end-point. The mean Positive subscale scores declined from 23.6¡4.3 to 17.0¡5.1. The mean Negative scores declined from 26.2¡5.8 to 22.0¡5.8, the General Psychopathology scores declined from 39.7¡9.0 to 31.2¡7.8, the Cognitive scores declined from 14.7¡4.3 to 11.5¡3.7, and the NOSIE total scores declined from 70.6¡12.2 to 57.7¡11.3. All these scores declined significantly (all p values=0.000). Table 2 , the two DRD2 genotype groups were similar in all baseline clinical measures. From baseline to study end-point, the Ser/Cys group of patients had significantly larger score reductions and percentage changes in negative symptoms than their counterparts (p=0.011 and 0.023 respectively). The Ser/Cys patients also had numerically (albeit statistically insignificant) larger score reductions and percentage changes at end-point in all other domains (particularly, p<0.1 for score reductions in PANSS Total and General Psychopathology as well as percentage changes in PANSS Total and Negative and Cognitive subscales, and NOSIE).
As shown in
As shown in Table 3 , after adjustment for treatment time effects, baseline psychopathology, risperidone dose, the 5-HT 2A T102C polymorphism, and other patient-related variables, the Ser311Cys polymorphism could influence performances in PANSS Total and subscales and in NOSIE : the Ser/Cys genotype was related with lower scores on all rating scales than the Ser/Ser genotype. In details, compared with patients who had the Ser/Cys genotype, the PANSS Total scores of patients with the Ser/Ser genotype were 7.77 % higher (e 0.0748 =1.0777, 1.0777x1=0.0777), their Positive subscale scores were 10.10 % higher (e 0.0962 = 1.1010), their Negative subscale scores were 8.57 % higher (e 0.0822 =1.0857), their General Psychopathology scores were 6.47 % higher (e 0.0627 =1.0647), their Cognitive subscale scores were 11.44 % higher (e 0.1083 = 1.1144), and their NOSIE total scores were 6.69 % higher (e 0.0648 =1.0669). If we controlled for all abovementioned variables but excluded 5-HT 2A T102C polymorphisms, the patients with the Ser/Cys genotype still had significantly better performance on all assessments than the wild-type individuals (results not shown).
The 5-HT 2A T102C polymorphism also had marginal influences on PANSS Total and Negative subscale scores (Table 3 ). Compared to patients who had the T/C genotype, those with C/C genotype had numerically (albeit statistically insignificant) lower scores in the PANSS Total (p=0.050) and the Negative subscale (p=0.055), but not in the Positive subscale or other scales. T/C and T/T genotypes were comparable in each PANSS subscale or NOSIE score. As also shown in Table 3 , higher end-point dose of risperidone, male gender, and fewer previous hospitalizations also predicted better clinical performance.
Further analysis revealed that the patients with the Ser/Cys genotype had a higher female to male ratio (9/3) than those with Ser/Ser (46/65) (p=0.034). The heterozygote group also tended to tolerate lower risperidone doses compare to the wild-type group (3.3¡ 1.2 mg/d vs. 4.1¡1.4 mg/d, p=0.071). These differences, however, should not have contributed to the superior clinical performance of the Ser/Cys patients because regression analyses, as shown above, revealed that female patients and lower doses were associated with inferior response to risperidone.
Discussion
To our knowledge, the present study is the first to investigate an association between atypical antipsychotic effects and the Ser311Cys polymorphism in the DRD2 gene. We found that, compared to the Ser311Ser genotype, the Ser311Cys genotype was associated with superior risperidone response (for positive, negative, and cognitive symptoms, general psychopathology, and even social function) in patients with acutely exacerbated schizophrenia. Our study results support the findings of previous studies (Arinami et al., 1994 ; Shaikh et al., 1994) : when treated with typical antipsychotics, patients carrying Cys311 had shorter duration of hospitalization or were less likely to be treatment-resistant than those without Cys311. Arinami et al. (1994) also found the DRD2 Cys allele to be a risk factor schizophrenia. Although a large number of replication attempts have failed, two recent meta-analyses (Glatt et al., 2003 ; Jonsson et al., 2003) substantiate the notion that the DRD2 Cys allele may be a risk factor for the development of schizophrenia. Taken together, these results support the involvement of the DRD2 gene in the pathogenesis of schizophrenia and perhaps treatment response of antipsychotics.
In accordance with our earlier finding in 100 patients (Lane et al., 2002a) , the current study in an extended sample showed that the 5-HT 2A T102C polymorphism could affect PANSS Total and Negative subscale scores (but not Positive subscale scores) with borderline significance. Although the T102C substitution does not alter amino-acid sequence, recent evidence (Polesskaya and Sokolov, 2002) indicates that total levels of 5-HT 2A receptor mRNA and protein in normal individuals with the C/C genotype are lower than in individuals with the T/T genotype.
Certainly, we might have had a chance false- positive finding. Although 123 subjects is a fairly robust sample size for a pharmacogenetic study, the low frequency of the Ser311Cys polymorphism results in a comparison of only 12 Ser/Cys heterozygotes to 111 Ser/Ser homozygotes (with no Cys/Cys homozygotes). Any conclusions drawn from this study should be tempered by the small sample of patients with the rarer allele. We thus consider the results to be preliminary. Moreover, the genetic effect on negative symptoms might have been secondary to the genetic effect on positive symptoms (Kane, 1994 ; Lane et al., 1999b) . Further studies in other ethnic populations, in chronically ill patients receiving long-term treatment (Masellis et al., 2000 ; Rietschel et al., 1999) , and in patients with predominantly negative symptoms (Lane et al., 1999b) are warranted. Possible effects of other DRD2 polymorphisms, such as x141C Ins/Del (Arranz et al., 1998a ; Malhotra and Goldman, 1999 ; Suzuki et al., 2001 ; Yamanouchi et al., 2003) and TaqI (Schafer et al., 2001 ; Yamanouchi et al., 2003) , on risperidone efficacy also require investigation. Finally, since risperidone also has effects on dopamine D 4 , histamine H 1 , adrenergic a 1 and a 2 (Meltzer, 1999) , and 5-HT 1A and 5-HT 2C receptors (Ichikawa et al., 2001 ; Tarazi et al., 2002) , the genetic effects of various receptors on risperidone efficacy should also be clarified (Kroeze and Roth, 1998 ).
In the current study, comorbid mood disorders were considered as exclusion criteria. Since DRD2 polymorphisms have been studies in pharmacogenetic studies in affective disorders (Serretti et al., 1999 (Serretti et al., , 2001 and risperidone has been shown to have an antidepressant activity (Lane and Chang, 1998 ; Myers and Thase, 2001) , further pharmacogenetic studies regarding mood effects of risperidone and polymorphisms of the DRD2 (or other receptors) may be of interest.
In an earlier study (Lane et al., 1999b) without controlling for Ser311Cys, gender effects on risperidone efficacy did not achieve statistical significance. In the current study, male patients responded better to risperidone than female patients after adjustment for the effects of genotypes and other patient-related variables. Similarly, schizophrenic males may be more likely to be good responders to clozapine (the prototype of atypical antipsychotics) than females (Lieberman et al., 1994) . Therefore, gender influences on treatment response may be different between atypical antipsychotics and typical ones (Lieberman et al., 1996) . The current study also revealed that higher risperidone dose (up to 6 mg/d, if tolerable) was related with better treatment response for both positive and negative symptoms. Further studies are needed.
There are several strengths in this study. We evaluated the therapeutic response directly from scores in the PANSS subscales and NOSIE rather than dichotomizing the patients into responders and non-responders, because response to antipsychotics is not pharmacogenetically dichotomous. Furthermore, instead of determining general response, positive, negative, and cognitive symptoms and social functioning were individually measured. Further, we controlled for other covariates such as treatment duration, baseline clinical manifestations, drug dosage, and other patient-related variables. We hope that this rigorous model could refine future pharmacogenetic or relevant genetic studies in neuropsychiatry.
